Merger creates precision medicine company focussed on next-gen targeted cancer therapies

Tango Therapeutics, a Cambridge, Mass-based biotech company discovering next-gen precision cancer medicines, is merging with BCTG Acquisition Corp, a special purpose acquisition company (SPAC) sponsored by Boxer Capital.

Upon closing of the transaction, the company will be named Tango Therapeutics, Inc. and will be led by Barbara Weber, President and CEO of Tango.

The deal creates a publicly listed precision medicine company focussed on developing next-gen targeted cancer therapies.

“This morning’s announcement is a key milestone for Tango as it ensures we have access to the capital needed to advance our preclinical programs and initiate clinical studies of our three lead programs, as we continue our mission of bringing transformational therapies to patients” said Dr. Weber.

Proceeds from the transaction are expected to provide Tango with the capital needed to further develop its pipeline.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news